Compare Inovio Pharmaceuticals Inc (INO) vs TKO Group Holdings Inc (TKO) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

TKO trades at $182.79, down 1.26% on the day, with a bearish technical signal from moving averages. The stock shows strong analyst support with 89% buy ratings and a consensus price target of $228.40. Recent financials indicate revenue growth to $5.1B in 2026 with a net income margin of 4.47%, though valuation ratios like a P/E of 67.95 appear elevated. Key developments include a completed $800 million share repurchase and strong UFC event viewership.

The outlook for TKO is positive based on robust analyst consensus and expanding monetization from media deals, but risks include high valuation and recent insider selling. Earnings momentum needs to justify premium multiples, with the next quarterly report on August 3, 2026, critical for confirming growth trajectory.